Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Arm, Phase 4 Study to Assess Glycemic Control When Adults With Type 2 Diabetes Switch From a GLP-1 RA to Tirzepatide (SURPASS-SWITCH-2)

NCT05706506 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05706506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05706506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Arm, Phase 4 Study to Assess Glycemic Control When Adults With Type 2 Diabetes Switch From a GLP-1 RA to Tirzepatide (SURPASS-SWITCH-2)
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
March 8, 2023
Completion date
October 31, 2023
Enrollment
152 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2, type 2 diabetes